Elderly transplant-ineligible (NTE) patients represent the majority of patients affected by multiple myeloma (MM). Elderly patients are a highly heterogeneous population, with large variability in health and functional status. Thus, choosing their optimal treatment is challenging. A wide range of first-line treatments is available, and novel-agent combinations, including monoclonal antibodies (mAbs), have recently entered clinical practice. The combination of the anti-CD38 mAb daratumumab with bortezomib, melphalan and prednisone (Dara-VMP) or lenalidomide and dex-amethasone (Dara-Rd) demonstrated impressive advantages in terms of progression-free survival and minimal residual disease negativity, as compared to VMP and Rd, without safety concerns. Another anti-CD38 mAb, isatuximab, is showing encouraging results, and new isatuximab-based combinations might enter clinical practice in the future. Nevertheless, available data come from clinical trials with selected patient populations and, to date, the manageability of these regimens in real-life patients or in frail patients remains unknown. Frailty-tailored treatments, including mAbs, are under evaluation in preliminary studies. In this review, we analyze recently approved mAb-based treatments for NTE newly diagnosed MM patients and new combinations under evaluation, focusing on the efficacy and safety of these regimens and on open issues regarding the choice of therapy for elderly patients.

The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma

Bonello F.
First
;
D'agostino M.;Boccadoro M.;Bringhen S.
Last
2021

Abstract

Elderly transplant-ineligible (NTE) patients represent the majority of patients affected by multiple myeloma (MM). Elderly patients are a highly heterogeneous population, with large variability in health and functional status. Thus, choosing their optimal treatment is challenging. A wide range of first-line treatments is available, and novel-agent combinations, including monoclonal antibodies (mAbs), have recently entered clinical practice. The combination of the anti-CD38 mAb daratumumab with bortezomib, melphalan and prednisone (Dara-VMP) or lenalidomide and dex-amethasone (Dara-Rd) demonstrated impressive advantages in terms of progression-free survival and minimal residual disease negativity, as compared to VMP and Rd, without safety concerns. Another anti-CD38 mAb, isatuximab, is showing encouraging results, and new isatuximab-based combinations might enter clinical practice in the future. Nevertheless, available data come from clinical trials with selected patient populations and, to date, the manageability of these regimens in real-life patients or in frail patients remains unknown. Frailty-tailored treatments, including mAbs, are under evaluation in preliminary studies. In this review, we analyze recently approved mAb-based treatments for NTE newly diagnosed MM patients and new combinations under evaluation, focusing on the efficacy and safety of these regimens and on open issues regarding the choice of therapy for elderly patients.
14
1
1
14
https://www.mdpi.com/1424-8247/14/1/20
https://doi.org/10.3390/ph14010020
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823261/
First-line treatment; Monoclonal antibodies; Multiple myeloma; New diagnosis; Transplant-ineligible patients
Bonello F.; Grasso M.; D'agostino M.; Celeghini I.; Castellino A.; Boccadoro M.; Bringhen S.
File in questo prodotto:
File Dimensione Formato  
[PUBLISHED Vsn.] Bonello et al - 2021 - Pharmaceuticals.pdf

Accesso aperto

Descrizione: [Published Vsn.] Bonello F et al. Pharmaceuticals (Basel). 2020 Dec 29;14(1):20. doi: 10.3390/ph14010020. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. Open access article. CreativeCommonsAttribution (CCBY) license (https://creativecommons.org/ licenses/by/4.0/). Available at: https://www.mdpi.com/1424-8247/14/1/20 | https://doi.org/10.3390/ph14010020 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823261/
Tipo di file: PDF EDITORIALE
Dimensione 634.22 kB
Formato Adobe PDF
634.22 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1790885
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 6
social impact